Introduction
Hepatitis B virus (HBV) is a small, enveloped, partially double-stranded DNA virus with strict tropism to human hepatocytes [1, 2] . Hepatitis B viral infection attacks the liver and can cause both acute and chronic diseases [2] . An estimated 240 million people are chronically infected with hepatitis, and over one million people die every year owing to complications of hepatitis B, including cirrhosis and liver cancer [3, 4] . Hepatitis B prevalence is highest in subSaharan Africa and East Asia, where between 5% and 10% of the adult population is chronically infected [5, 6] .
The genotypes of HBV are defined by an intergroup divergence of more than 8% in the entire genome sequence [7, 8] . To date, 10 distinct genotypes (A-J), which show a distinct geographic distribution, have been described [9] [10] [11] [12] . Genotypes A and D are ubiquitous but most prevalent in Europe and Africa, whereas genotypes B and C are confined to Asia and Oceania. Genotypes E, F, G, and H are also occasionally observed in Asia. Though rare, genotype I is found in Laos, Vietnam, India, and China, and Genotype J has been described in Japan. Genotypes A-D are common and constitute 97% of the total patient population, whereas genotypes E-G represent less than 2% [13, 14] .
The hepatotropism of HBV is partially attributed to the entry step mediated by viral envelope proteins. The HBV envelope contains three membrane glycoproteins, namely the large, middle, and small surface proteins, which are translated from a single open reading frame via different in-frame start codons. The small surface protein is the major component of the viral envelope. The middle protein has an extra N-terminal preS2 region, whereas the large protein, on the basis of the middle protein, harbors an additional preS1 region of 108 aa (genotypes D and J) or 119 aa (the other subtypes) [15, 16] . Cell entry of HBV presumably begins with reversible, low-affinity attachment of HBV to the cell membrane via the interaction between viral envelope proteins and heparin sulfate proteoglycan, followed by high-affinity binding of viral envelope proteins to a specific receptor, the bile-acid pump sodiumtaurocholate cotransporting polypeptide (NTCP) [17] [18] [19] [20] . NTCP is an integral membrane protein that is exclusively expressed on the basolateral membrane of hepatocytes, which explains the tropism of HBV for the liver. Multiple lines of evidence have indicated that preS1, in particular, the N-terminal half (aa 2-47, genotype D) and the myristolyl moiety at its amino terminus, is critical for the binding of viral particle to NTCP, whereas aa 9-18 of the preS1 component (genotype D) are essential for HBV attachment and subsequent infection [21, 22] . Therefore, inhibition of virus entry that can neutralize the activities of viral surface proteins or target the cellular receptors has become a major concept in the development of new antiviral drugs.
Monoclonal antibodies (mAbs) have great potential for both diagnostic and therapeutic applications [23] . Murine mAbs are easy to produce, but their therapeutic use in humans is limited because of the human anti-mouse antibody response during treatment [24] . To obviate this problem, humanized antibodies have been constructed by grafting the complementarity determining regions (CDRs) of murine mAbs, which form an antigen-binding pocket, onto homologous human antibody variable domains, while retaining some murine residues in framework regions (FRs) that are predicted to influence the conformation of CDRs. This humanization technique is referred to as CDR grafting [25, 26] .
We previously generated two murine mAbs, KR359 and KR127, which recognize aa 19-26 and 37-45 of preS1 (genotype C), respectively [27] , and demonstrated that they exhibit neutralizing activity in infection of human hepatocyte primary culture by HBV in vitro [28] . Subsequently, we constructed a humanized version (HzKR127) of KR127 by CDR grafting and provided evidence that this humanized antibody can neutralize HBV infection in chimpanzees [29] . In addition, we developed an improved version (HzKR127-3.2) of HzKR127 through further humanization and affinity maturation [30] . In the present study, we constructed a humanized version (HzKR359-1) of KR359 via the CDRgrafting method and characterized its binding capacities to the preS1 region of HBV genotypes (A-J). In addition, we analyzed the binding capacities of HzKR127-3.2 and combined binding activities of HzKR359-1 and HzKR127-3.2 to the preS1 region of HBV genotypes. The results indicate that the combination of these two humanized antibodies can bind to most HBV genotypes and thus may broadly neutralize HBV infection.
Materials and Methods

Cell Culture
Murine hybridoma KR359 [27] cells were routinely cultured at 5% CO 
Construction of Humanized Antibody HzKR359-1
For the cloning of the cDNAs encoding the mouse heavy chain variable region (V H ) or κ light chain variable region (V κ ) of KR359 antibody (IgG1, κ), total RNA was isolated from the KR359 hybridoma, and the first-strand cDNA was synthesized from the total RNA using reverse transcriptase (Superscript II, Thermo Fisher Scientific) and the 3'-primers specific to the γ1 heavy (C 
Expression and Purification of Humanized Antibody
The heavy and light chain expression plasmid DNAs were mixed with polyethyleneimine (PEI, linear 25 kDa; Polysciences, USA) at a ratio of 1:4 (60 μg:240 μg) and incubated at room temperature for 25 min, as described previously [31] . The mixture was added to 30 ml of HEK293F cells (1.0 × 10 6 cells/ml) and cultured for 7 days. The culture supernatant was recovered by centrifugation at 2,300 ×g for 30 min at 4°C and subjected to indirect ELISA and quantitative ELISA to determine its antigenbinding activity. For purification of the humanized antibody, the culture supernatant was subjected to affinity chromatography on Protein A-agarose beads (Amicogen, Inc., Korea). The antibody was eluted from the column with 0.1 M sodium citrate buffer (pH 3.2) and neutralized with 1.0 M Tris-HCl buffer. Finally, the buffer was changed to storage buffer (25 mM sodium citrate, 150 mM NaCl, pH 6.4) by using Vivaspin (MWCO 30,000; Sartorius, Germany), as described previously [32] . Antibody concentration was determined with a NANO-DROP 2000 spectrophotometer (Thermo Fisher Scientific) based on the molar extinction coefficient. The integrity and purity of the purified antibody were analyzed by SDS-PAGE and western blot analysis.
Construction, Expression, and Purification of Recombinant PreS1 Antigens
For the production of recombinant preS1 antigens of six HBV genotypes (B-G), the preS1 sequences (aa 1-60) of the HBV genotypes were individually synthesized and fused to the Cterminus of the Ig1-Ig5 domains of human L1 cell adhesion molecule (L1CAM), whereas a Strep-tag II sequence (Trp-Ser-HisPro-Gln-Phe-Glu-Lys) was fused to the C-terminus of the preS1 sequence for the detection and purification of the recombinant preS1 antigen. The preS1 sequences were derived from the GenBank database. The accession numbers of the genotype sequences are genotype A (AB014370), genotype B (AB014366), genotype C (AB014360), genotype D (AB090270), genotype E (AB091255), genotype F (AB036950), genotype G (AB056513), genotype H (AB298362.1), genotype I (AF241407), and genotype J (AB486012.1) [12, 33, 34] . The preS1-Strep-tag II sequence was synthesized and subcloned into the XhoI-ApaI sites of pIg5-hFc [32] to construct pIg5-preS1-strep, and then the Ig1-Ig5 sequence was subcloned into the EcoRI-XhoI sites of pIg5-preS1-strep to construct expression plasmid pIg1-5-preS1-strep.
The expression plasmid was introduced into HEK293F cells using PEI, and the recombinant preS1 antigen was transiently expressed for 7 days, as described above. The culture supernatant was subjected to indirect ELISA and quantitative ELISA to assess the antibody-binding activity. For protein purification, the culture supernatant was subjected to affinity chromatography on a Streptactin Superflow high capacity column (Iba, Germany), according to the protocol suggested by the supplier. Briefly, the column was equilibrated with buffer W (100 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1 mM EDTA) and the bound protein was eluted with 5 column volumes of buffer W supplemented with 2.5 mM desthiobiotin. Finally, the buffer was changed to PBS. The protein concentration was determined using the NANO-DROP 2000 spectrophotometer, and the integrity of the purified protein was assessed by western blot analysis.
Western Blot Analysis
The purified HzKR359-1 antibody was analyzed by 10% SDS-PAGE under reducing conditions and 6% SDS-PAGE under nonreducing conditions, followed by Coomassie Brilliant Blue G-250 staining. The protein bands were transferred to a nitrocellulose membrane (GE Healthcare, France), and then the membrane was incubated with anti-human IgG(H+L)-HRP conjugate (1:10,000 (v/v); Thermo Fisher Scientific). Finally, the bands were visualized using a chemiluminescent substrate (WEST-ZOL plus; iNtRON BioTechnology, Korea).
For the recombinant preS1 antigens, the purified proteins were subjected to 10% SDS-PAGE and western blot analysis with a murine mAb A10-A3 (0.5 μg/ml) that binds to the Ig1 domain of human L1CAM [35] , followed by anti-mouse IgG (Fc-specific)-HRP conjugate (1:6,000 (v/v); Thermo Fisher Scientific).
Enzyme-Linked Immunosorbent Assays
All the incubations were performed at 37 . The optical density was read at 450 nm in a microplate reader (Molecular Devices, USA).
For competitive ELISA, HzKR359-1 and increasing concentrations of KR359 as a competing antibody were incubated with the preS1 antigen (genotype C) used as a coating antigen, and the bound humanized antibody was detected using anti-human IgG (Fcspecific)-HRP, while KR359-1 and increasing concentrations of HzKR359-1 were incubated with the preS1 antigen, and the bound mouse antibody was detected using anti-mouse IgG(Fc-specific)-HRP (1:6,000; Thermo Fisher Scientific). Herceptin was used as an irrelevant antibody control in this assay.
Analysis of Humanized Antibody Using Octet Red
The anti-human Fc-coated biosensor (Fortebio, Inc., USA) was activated in 0.1% PBA (PBS containing 0.1% BSA) for 20 min by agitating at 1,000 rpm. Antibody (1 μg/ml) was captured for 10 min and then washed with 0.1% PBA for 2 min. For affinity determination, the sensor-loaded antibody was incubated with the preS1 antigen (100, 50, 25, 12.5, or 6.25 nM in 0.1% PBA) for 10 min for the association step. Then, the dissociation step was carried out in 0.1% PBA for 30 min. The sensor without loading antibody was used as a reference well. The whole experiment process was performed at 30 o C and by agitating at 1,000 rpm. Data were analyzed using a 1:1 interaction model with a ForteBio data analysis software ver. 7.1.
For the analysis of additive binding of two mAbs to the preS1 antigen, the sensor-loaded humanized antibody was incubated with the preS1 antigen (100, 50, or 25 nM in 0.1% PBA) for 10 min, and then incubated with mouse antibody binding to a different epitope. Baselines were established before and after the loading step. The expression plasmids were cotransfected into HEK293F cells, and the resulting humanized antibody (HzKR359-1) was transiently expressed and purified from the culture supernatant by affinity chromatography on a Protein A column. The purity and integrity of the purified antibody were confirmed by SDS-PAGE (Fig. 1A) and western blot analysis using anti-human IgG-HRP (Fig. 1B) under reducing and non-reducing conditions.
Results and Discussion
Construction, Expression, and Purification of Recombinant PreS1 Antigens of Six Different HBV Genotypes
To produce the recombinant preS1 antigens, the Ig1-Ig5 domains of human L1CAM were used as a carrier protein because these domains were found to be stably expressed in mammalian cells and secreted well in our previous study [35] , and a Strep tag was fused to the C-terminus of preS1 for the detection and purification of the recombinant preS1 antigen (Fig. 2A) . The amino acid sequences of the preS1 region (aa 1-60) of 10 HBV genotypes (A-J), including the essential NTCP-binding site (aa [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and the epitopes of HzKR359-1 (aa 19-26) and HzKR127-3.2 (aa 37-45), are shown in Fig. 2B . Comparison of the epitope sequences among the genotypes indicated that five genotypes (A, B, C, H, and J) have the same epitope sequence of HzKR359-1, whereas three genotypes (A, C, and I) have the same epitope sequence of HzKR127-3.2. Therefore, the preS1 antigens of six HBV genotypes (B-G) were produced to examine the antigen-binding activity of HzKR359-1 or HzKR127-3.2 to all of the HBV genotypes (A-J).
For the production of the preS1 antigens, the preS1 sequences of the six genotypes (B-G) with Strep tags were synthesized and individually fused to the C-terminus of the Ig1-Ig5 domains. The recombinant preS1 fusion proteins were transiently expressed in HEK293F cells, and the culture supernatants were subjected to quantitative ELISA using a murine anti-L1CAM mAb (A10-A3) as a coating antigen and anti-Strep Tag-HRP to measure their expression levels. As a result, the preS1 antigens of the genotypes B-D (2.4-4.2 µg/ml) were expressed at higher levels than those of genotypes E-G (0.7-0.9 µg/ml; data not shown). The preS1 antigens were purified from the culture supernatants using a Strep tag and subjected to western blot analysis using A10-A3 antibody. The result showed that the preS1 antigens were stably expressed and purified (Fig. 2C) .
Analyses of Antigen-Binding Activity and Affinity of HzKR359-1
The antigen-binding activity of the purified HzKR359-1 antibody was analyzed by indirect ELISA using the purified preS1 antigen (genotype C) as a coating antigen. HzKR359-1 bound to the preS1 antigen in a dose-dependent manner, and its antigen-binding activity was slightly lower than that of HzKR127-3.2, which was developed through affinity maturation of a humanized KR127 antibody constructed by CDR grafting (Fig. 3A) . The data indicate that the HzKR359-1 antibody was successfully constructed.
To compare the antigen-binding activity of HzKR359-1 with that of KR359, competitive ELISAs were performed. HzKR359-1 and increasing concentrations of KR359 as a competing antibody were incubated with the preS1 antigen (genotype C) coated on the well, and the bound humanized antibody was detected using anti-human IgG (Fc-specific)-HRP, whereas anti-HER2 humanized antibody (Herceptin) was used as an irrelevant antibody control (Fig. 3B) . Similarly, KR359-1 and increasing concentrations of HzKR359-1 were incubated with the preS1 antigen, and the bound mouse antibody was detected using anti-mouse IgG-HRP (Fig. 3C) . The results indicated that HzKR359-1 and KR359 competed for the same epitope, indicating that HzKR359-1 retained the same epitope specificity as that of KR359. The IC 5 0 of HzKR359-1 was calculated to be 0.37 µg/ml (Fig. 3C ), whereas that of KR359 was 1.62 µg/ml (Fig. 3B) , indicating that the antigen-binding activity of HzKR359-1 is higher than that of KR359.
To precisely compare the affinity of HzKR359-1 with that of HzKR127-3.2, the affinities of these antibodies for the preS1 antigen (genotype C) were measured using Octet Red. As shown in Fig. 4 , the affinity (3.28 × 10 -9 M) of HzKR359-1 was 5.8-fold lower than that (5.69 × 10
Analyses of the Antigen-Binding Activities of HzKR359-1 or HzKR127-3.2 to Different HBV Genotypes Having analyzed the antigen-binding activities of HzKR359-1 and HzKR127-3.2 to the preS1 of genotype C, we further extended the analysis to other genotypes. Because the epitope sequences of HzKR359-1 and HzKR127-3.2 in genotype A are identical to those in genotype C, we exempted the expression of the preS1 antigen of genotype A. HzKR359-1 or HzKR127-3.2 was incubated with each of the purified recombinant preS1 antigens of genotypes (B-G), bound by anti-L1CAM antibody (A10-A3) coated on the well, to perform indirect ELISA. The results showed that HzKR359-1 bound to the preS1 of genotypes B and C (Fig. 5A) , whereas HzKR127-3.2 bound to genotypes C, D, and G (Fig. 5B) . Accordingly, HzKR359-1 plus HzKR127-3.2 bound to genotypes B, C, D, and G (Fig. 5C) . Considering that the epitope sequences of HzKR359-1 and HzKR127-3.2 in genotype A are identical to those in genotype C, HzKR359-1 can bind to the preS1 of three genotypes (A-C), whereas HzKR127-3.2 can bind to four genotypes (A, C, D, and G) .
Given that the epitope sequences of HzKR359-1 in genotypes H and J are identical to those in genotypes A-C, HzKR359-1 is expected to bind to five genotypes (A-C, H, and J). Likewise, because the epitope sequence of HzKR127-3.2 in genotype I is identical to that in genotypes A and C, HzKR127-3.2 is predicted to bind to five genotypes (A, C, D, G, and I). Collectively, the combination of HzKR359-1 and HzKR127-3.2 is expected to bind to eight genotypes (A-D and G-J), except genotypes E and F. Considering that genotypes E and F are occasionally represented in small patient populations, the combination of HzKR359-1 and HzKR127-3.2 may bind to HBV particles of most genotypes.
Additive Binding of HzKR359-1 and HzKR127-3.2 to Genotype C Because the epitope of HzKR359-1 is only 11 aa distant from that of HzKR127-3.2, we examined whether these two antibodies compete in binding to the preS1 antigen of genotype C, using competitive binding assay. As shown in Fig. 6A, HzKR359-1 or Herceptin as a negative control did not inhibit the binding between KR127 and the preS1 antigen, whereas HzKR127-3.2 efficiently inhibited binding, suggesting that HzKR359-1 and HzKR127-3.2 can bind to genotype C simultaneously. To demonstrate this, HzKR359-1 or HzKR127-3.2 was incubated with different concentrations of the preS1 antigen followed by KR127 or KR359, respectively, using Octet Red (Figs. 6B and 6C) . Indeed, HzKR359-1 and KR127 (or HzKR127-3.2 and KR359) bound to the preS1 antigen additively and, thus, showed enhanced binding activity to genotype C compared with either antibody alone.
In conclusion, we successfully constructed a humanized antibody (HzKR359-1) that binds to the essential receptor binding site and demonstrated that the affinity of HzKR359-1 is higher than that of the original murine mAb. HzKR359-1 can bind to five genotypes (A-C, H, and J), and HzKR127-3.2 binds to six genotypes. The combination of HzKR359-1 and HzKR127-3.2 can bind to most HBV genotypes, with the exception of genotypes E and F, and showed enhanced binding to genotype C compared with that of either antibody alone. Given that HzKR127 exhibited neutralizing activity to genotype C in chimpanzees and that the epitopes of HzKR359-1 and HzKR127-3.2 are located in the receptor-binding site, these two humanized antibodies might effectively block the entry of most virus genotypes and thus broadly neutralizing HBV infection. (A) Competition ELISA of KR127 using HzKR359-1 or HzKR127-3.2 as competing antibody. The data are presented in Sigma plots. The optical density obtained from the control (no competitor) was considered as 100%. Herceptin was used as an irrelevant antibody (negative control). (B and C) Additive binding analysis of HzKR127-3.2 and KR359 (B) or HzKR359-1 and KR127 (C) using Octet Red. PreS1 concentrations used are 100, 50, and 25 nM. As a control, PBS containing 0.1% BSA was used in place of the antigen or antibodies.
